Public documents that mention Mark Dallas Loeffler.
May 20, 2026·Board meeting
Oversight Committee Meeting
The committee meeting covered a wide range of administrative, compliance, and programmatic topics. These included CEO, compliance, scientific, and product development officer reports, alongside recommendations for academic research and product development grant awards. Discussions also encompassed the appointment of members to various advisory and scientific research committees, proposed amendments to administrative rules, financial status updates, legislative appropriation requests, and bond issuance resolutions. Additionally, the committee addressed internal audit reports, compliance training, and preparations for upcoming conferences.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The meeting included reports from the CEO, Chief Compliance Officer, Chief Scientific Officer, Interim Chief Prevention Officer, and Chief Product Development Officer. Key discussion points included FY 2025 grant funds, personnel updates, the 89th Legislative Session, grantee reports, compliance attestations, and grant award recommendations for various programs. The committee also addressed appointments to scientific research and prevention programs, the FY 2026 honoraria policy, advisory committee appointments, and presentations. Additionally, the committee discussed health and safety code waivers, the chief financial officer's report, contract approvals, internal auditor reports, the 2026 CPRIT Innovations VII Conference, grant management platform modernization assessment, communications updates, subcommittee business, election of board officers, and future meeting dates.
May 21, 2025·Board meeting
Oversight Committee Meeting
The meeting included the CEO's report, which covered FY 2025 grant funds, personnel, and legislative updates. The Chief Compliance Officer reported on grantee reports, financial status report reviews, desk reviews, site visits, annual compliance attestation, audit tracking, and training. The Chief Scientific Officer provided an update on the Academic Research Program and presented award recommendations and FY 2026 requests for applications. The Chief Prevention Officer updated the committee on the Prevention Program and presented award recommendations. The Chief Product Development Officer provided an update on the Product Development Research Program and presented award recommendations. The committee also discussed the Internal Auditor Report, appointments to the Scientific Research and Prevention Programs Committee, Advisory Committee appointments, the Chief Financial Officer Report, the FY 2026 Bond Issuance Resolution, Contract Renewal and Approvals, a Communications Update, and Personnel matters.
